236 related articles for article (PubMed ID: 12431678)
1. The efficacy of mycophenolate mofetil treatment in the prevention of acute renal rejection is related to plasma level of mycophenolic acid.
Kuriata-Kordek M; Boratyńska M; Klinger M; Woźniak M; Urbaniak J; Szyber P; Patrzalek D; Tupka D
Transplant Proc; 2002 Nov; 34(7):2985-7. PubMed ID: 12431678
[No Abstract] [Full Text] [Related]
2. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment.
Engelbertink R; Smak Gregoor P; Hesse C; IJzermans J; Weimar W; van Gelder T
Transplant Proc; 2002 Nov; 34(7):2983-4. PubMed ID: 12431677
[No Abstract] [Full Text] [Related]
3. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
4. Mycophenolate mofetil in living donor renal allograft recipients.
Park K; Moon JI; Kim SI; Kim YS
Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
[No Abstract] [Full Text] [Related]
5. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
[No Abstract] [Full Text] [Related]
6. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
[No Abstract] [Full Text] [Related]
7. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
Remport A; Sasvári I; Toronyi E; Borka P; Lázár N; Járay J; Perner F
Transplant Proc; 2001 May; 33(3):2302-3. PubMed ID: 11377537
[No Abstract] [Full Text] [Related]
8. Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant.
Mohammadpur AH; Nazemian F; Abtahi B; Naghibi M
Exp Clin Transplant; 2008 Dec; 6(4):276-81. PubMed ID: 19338489
[TBL] [Abstract][Full Text] [Related]
9. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
10. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
[No Abstract] [Full Text] [Related]
11. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.
Nicholls AJ
Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients.
Aigrain EJ; Shaghaghi EK; Baudouin V; Popon M; Loirat C
Transplant Proc; 2000 Mar; 32(2):388-90. PubMed ID: 10715449
[No Abstract] [Full Text] [Related]
13. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
[No Abstract] [Full Text] [Related]
14. Pharmacokinetic study of mycophenolate mofetil in Asian renal transplant recipients.
Yeung S; Tong KL; Tsang WK; Chan HW; Chan AY
Transplant Proc; 2000 Nov; 32(7):1753-4. PubMed ID: 11119920
[No Abstract] [Full Text] [Related]
15. Therapeutic drug level monitoring for mycophenolate mofetil: is it justified?
Stephan A; Masri MA; Barbari A; Kamel G; Karam A; Kilani H
Transplant Proc; 2001 Aug; 33(5):2778-9. PubMed ID: 11498157
[No Abstract] [Full Text] [Related]
16. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
Crespo JF; Górriz JL; Sancho A; Avila A; Alcoy E; Pallardó LM
Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
[No Abstract] [Full Text] [Related]
17. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients.
Budde K; Braun KP; Glander P; Böhler T; Hambach P; Fritsche L; Waiser J; Mai I; Neumayer HH
Transplant Proc; 2002 Aug; 34(5):1748-50. PubMed ID: 12176561
[No Abstract] [Full Text] [Related]
19. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.
Smak Gregoor PJ; Hesse CJ; van Gelder T; van der Mast BJ; IJzermans JN; van Besouw NM; Weimar W
Transplant Proc; 1998 Jun; 30(4):1192-3. PubMed ID: 9636482
[No Abstract] [Full Text] [Related]
20. Drug monitoring of mycophenolic acid in the early period after renal transplantation.
Krumme B; Wollenberg K; Kirste G; Schollmeyer P
Transplant Proc; 1998 Aug; 30(5):1773-4. PubMed ID: 9723276
[No Abstract] [Full Text] [Related]
[Next] [New Search]
